High-dose therapy followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory/relapsed indolent nonHodgkin (iNHLs) and mantle cell lymphomas (MCLs) has shown significant improvement regarding PFS and overall survival (OS). iNHLs are also known to be highly radiosensitive diseases. Radio immunotherapy (RIT) approach such as 90 Y-ibritumomab-tiuxetan ( 90 YIT, Zevalin, Bayer Schering Pharma AG, Berlin, Germany) combined with high-dose chemotherapy protocols like BEAM (carmustine, etoposide, cytarabine and melphalan) were developed in an attempt to improve the antitumoral potency of the conditioning regimens. Since 2006, several studies have described promising results in relapsed or refractory NHLs with heterogeneous cohorts including iNHLs but also a majority of aggressive lymphomas. [1] [2] [3] [4] [5] Only one phase II prospective study in indolent lymphomas showed a benefit of 90 YIT in association with BEAM (Z-BEAM) as intensive therapy. 6 There is a lack of data about the efficacy and safety of Z-BEAM conditioning regimen in iNHLs especially because of short follow-up in the published data. We report here the outcome from a cohort of high-risk iNHL treated with 90 YIT added to BEAM regimen (Z-BEAM) for ASCT with sustained follow-up in a single French center.
When our first patient received Z-BEAM, the lack of scientific data precluded conclusion about the risk/benefit ratio of such intensive therapy including RIT. Considering this lack of data, the French health authority authorized in 2006 such strategy with RIT as an exceptional prescription and Zevalin was reimbursed by social security. Regarding the promising data published 7 when associated with BEAM and the weak toxicity we experienced within its approved indication, we decided in 2006 to associate Zevalin with intensive chemotherapy as soon as a patient required autologous transplantation for indolent lymphoma. Thus, 14 consecutive patients suffering from iNHL/high-risk MCL in the Department of Hematology in Besancon University Hospital (France) between June 2006 and July 2009 were proposed for ASCT with Z-BEAM as the conditioning regimen. We report here the outcome of those patients. In order to stress our results, we will report at the same time a control group treated with BEAM regimen in our center and recruited between 2001 and 2009. The Table 1 shows characteristics of the both cohorts. All patients gave their informed consent to the collection and analyses of their data according to the French standards and to the declaration of Helsinki. Briefly, PBSC were collected by apheresis after mobilization with SC hematopoietic growth factor support as already described. 8, 9 The transfused graft had to contain more than 4 × 10 6 CD34 + cells/kg to be included in our study. In Z-BEAM regimen, Rituximab (F. Hoffmann-La Roche, Basel, Switzerland) was first injected in purpose to promptly saturate all natural nontumoral antigenic site before the radionucleotid infusion. 90 YIT 15 MBq/kg (0.4 mCi/kg) infusion was administered with a maximum total dose of 1200 MBq (32mCi) in the Nuclear Medicine department within our hospital. Then BEAM regimen was administered as already described. 8 The autologous graft was infused at least 24 h after the last chemotherapy administration. All patients were treated in the same conditions according to the standard practices and recommendations as described in our standard institutional protocols. 10 Only supportive care may have been modified during the period study, especially for the BEAM cohort for which the first patient was treated in 2001. We defined engraftment when absolute neutrophil count is superior to 0.5 × 10 9 /L and platelets superior to 20 × 10 9 /L for two consecutive days.
Patients' characteristics were roughly similar between the patients received a Z-BEAM and the control group receiving BEAM alone as conditioning regimen followed by ASCT ( Table 1 ). The main difference between the cohorts lies in the histological type. In the Z-BEAM group, 5 (35%) patients with aggressive disease were transplanted after completing their first remission: 1 follicular lymphoma (FL) with histological grade 3b, 2 follicular lymphomas in transformation (FLts), 1 MCL with a high-tumor burden and 1 marginal zone lymphomas with aggressive histological characteristics. In the BEAM group, 17 patients (17.5%) were transplanted in first remission: 2 LFs with a hightumor burden, 14 suffering from FLts and 2 with MCLs.
There were no differences in engraftment kinetics between the two treatment groups, and those data were similar to those published in previous prospective studies. 6, 8, 9, 11 Time to absolute neutrophil count recovery was 12 days vs 10.5 day (P = 0.069) and time to platelet recovery was 12 vs 13 days (P = 0.45). One patient in the Z-BEAM group had a prolonged aplasia despite a transfused CD34 + cells count 44 × 10 6 /kg. The median number of red blood cell transfusions was 2 and 4 units (P = 0.0145) in the Z-BEAM and BEAM groups, respectively. Red blood cell transfusions were more frequent with BEAM than with Z-BEAM and might be explained in part with the observation of a more frequent use of recombinant EPO in the pre-transplant period, which is known to reduce transfusions needs. 12 As previously reported in a randomized study, 5 the most common toxicities after ASCT after Z-BEAM were grade 3 infections (42.8%) and all 6 have been microbiologically documented: invasive pulmonary aspergillosis, Enterococus faecium colitis, Enterobacter cloacae colitis, Staphylococcus bacteremia, Cryptosporidiose colitis and Citrobacter cloaque cystis. Six patients presented grade 3 mucositis (42.8%) similar to the Terriou et al. No death was observed during the first 100 days post transplantation. Interestingly, no secondary malignancy was observed in Z-BEAM with a median follow-up of 52.7 months (range 2.4-86.6 months) although nine cases were reported in the BEAM group after a longer median follow-up of 70.6 months (range 4.2-144.5 months). We report three myelodysplastic syndromes/acute myeloid leukemia (39, 46 and 68 months, respectively) and six solid tumors (from 21 to 107 months). These data confirm the safety of Z-BEAM conditioning regimen in this setting and correlate with the low risk of therapy-related malignancies already mentioned after RIT. 13 Overall response rate is 100% in our Z-BEAM group like that shown in prospective studies 8, 9, 11 and in GELA's study including 87% of FLs 6 ( Table 2) . After a median follow-up of 52.7 months (range 2.4-86.6 months), 10 patients relapsed (71%) in the Z-BEAM group. In the BEAM group, 15 patients relapsed (37.5%) with a longer median follow-up of 70.6 months (range 4.2-144.5 months). The median time to relapse is 21.5 months in the Z-BEAM group vs 18 months in the BEAM group (P = 0.78). This trend for better outcome in the control group could be explained by the heterogeneity of the cohort, and especially by the aggressive features of the iNHL into the Z-BEAM group including 42.8% of MCLs and 28.5% of FLts as summaries in Table 1. 14 Despite a high rate of relapse in Z-BEAM group, all patients were able to receive salvage chemotherapy for post-ASCT relapse and two patients received an allogeneic transplant. This observation supports the fact that hematopoietic capacity after RIT is sufficient to allow further treatments. 15 Currently, 7 patients (50%) in the Z-BEAM group are alive in continuous CR: 3 FL, 1 MZL, 3 MCLs, and 3 FLts and 6 patients died after post autograft relapse. In the BEAM group, 29 (72.5%) patients are alive and 11 (27.5%) patients died: 5 from relapse, 1 died of cerebral hemorrhage, 2 of interstitial lung disease, 1 of lung adenocarcinoma, 1 after a car accident and 1 of secondary AML. Among relapse after BEAM, 1 patient received a second autograft with 90 YIT included in the conditioning regimen and 5 patients received an allogeneic transplant. Among them, 2 patients received a conditioning regimens including 90 YIT. Although a low toxicity is encountered after Z-BEAM, outcome does not significantly differ between the two groups and there is a trend for better results in the control group. Indeed, the 4-year OS is 64.3 and 83.9% (P = 0.20) and the 4-year PFS is 28.6 and 54.7% in the Z-BEAM and BEAM group, respectively (P = 0.05). The median time for PFS is 25 months in the Z-BEAM group, and is not achieved in the BEAM group. In our retrospective study of unselected subjects suffering from indolent lymphoma with aggressive feature, we emphasize no additive effect with addition of Zevalin on OS as already shown in a previous retrospective comparative study presented at ASH meeting in 2012. 3 Table 2 gathers prospective and retrospective communicated data assessing Z-BEAM conditioning in indolent lymphoma. Only one of those studies is finally designed with a control group of ASCT without RIT. At least, they all validated safety and efficacy of Abbreviations: DLBCL = diffuse large B-cell lymphoma; EFS = event-free survival; FL = follicular lymphoma; FLt = transformed follicular lymphoma; MCL = mantle cell lymphoma; MZL = marginal zone lymphoma; ORR = overall response rate; OS = overall survival.
Letter to the Editor Z-BEAM and they suggested its assessment in first relapse patients.
The retrospective nature of our study and the lack of strict matching with the control group, leads to caution for the mounting conclusion on the choice of intensive therapy with or without RIT for iNHL. Nevertheless, this work demonstrates the safety of 90 YIT combined with BEAM with an adequate follow-up. By presenting such retrospective monocentric series, we may feed new thought on how use radio-immunotherapy in iNHL in relapse and would suggest redirecting its use in hematological malignancies.
